To overcome this therapy resistance, Lemos and colleagues showed that in mice bearing established Lewis lung carcinoma (LLC) tumours, intratumoural treatment with STING agonist, synthetic cyclic diadenyl monophosphate (CDA) and co‐treatment with selective COX2 inhibitor celecoxib eliminated the primary tumour burden, prevented metastases and induced durable protective antitumour immunity.61 The gene discussed is STING1; the disease is neoplasm.